title: Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy.
authors.forename: P
authors.initials: P
authors.lastname: Niscola
authors.forename: M I
authors.initials: MI
authors.lastname: Del Principe
authors.forename: L
authors.initials: L
authors.lastname: Maurillo
authors.forename: A
authors.initials: A
authors.lastname: Venditti
authors.forename: F
authors.initials: F
authors.lastname: Buccisano
authors.forename: D
authors.initials: D
authors.lastname: Piccioni
authors.forename: S
authors.initials: S
authors.lastname: Amadori
authors.forename: G
authors.initials: G
authors.lastname: Del Poeta
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006509:Hepatitis B / Q000209:etiology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D014775:Virus Activation / Q000187:drug effects*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D006514:Hepatitis B Surface Antigens; D000069283:Rituximab